Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients

NCT07315139 | Completed

• 1 other identifier: FMASU MS 53/2023
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to determine the impact of Pentoxifylline on inflammatory biomarkers and the progression of chronic kidney disease in non-diabetic patients.

Conditions

Pentoxifylline; Inflammatory Markers; Non-Diabetic; Chronic Kidney Disease

Outcome Measures

Primary Outcomes (1)

• Levels of inflammatory marker

  Levels of inflammatory marker was recorded.

  3 months post-procedure

Study Arms (2)

Group 1

ACTIVE COMPARATOR

Patients received the standard therapy. The routine standard consisted of angiotensin-converting enzyme inhibitors (ACEI) (Ramipril 1.25 mg), a calcium-based phosphate binder (calcium acetate 700 mg, containing 180 mg of calcium), alfacalcidol (0.25 µg), antihypertensive medications, and diuretics.

Drug: Angiotensin-converting enzyme inhibitors (Ramipril)

Group 2

EXPERIMENTAL

Patients received one capsule of Pentoxifylline 400 mg twice daily for 6 months, in addition to their standard therapy.

Drug: Pentoxifylline

Interventions

Angiotensin-converting enzyme inhibitors (Ramipril) DRUG

Patients received the standard therapy. The routine standard consisted of angiotensin-converting enzyme inhibitors (ACEI) (Ramipril 1.25 mg), a calcium-based phosphate binder (calcium acetate 700 mg, containing 180 mg of calcium), alfacalcidol (0.25 µg), antihypertensive medications, and diuretics.

Group 1

Pentoxifylline DRUG

Patients received one capsule of Pentoxifylline 400 mg twice daily for 6 months, in addition to their standard therapy.

Group 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ˃ 18 years old.
• Both sexes.
• Patients with chronic kidney disease (CKD) stages G3, G4.
• Patients with proteinuria \< 1 g.

You may not qualify if:

• Patients who are terminally ill.
• Patients with Diabetes mellitus.
• Patients with proteinuria \> 1 g.
• Patients with a history of hemodialysis.
• Patients with active infection or hospitalized.
• Patients with recent cerebral and /or retinal Hemorrhage.
• Patients taking warfarin or theophylline-containing drugs.
• women who are taking oral contraceptives, pregnant, or lactating
• Patients with a history of adverse reactions to Pentoxifylline.
• Patients with polycystic kidney disease.
• Patients with obstructive uropathy.

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ain Shams University

Cairo, 11591, Egypt

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

Angiotensin-Converting Enzyme Inhibitors; Ramipril; Pentoxifylline

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Protease Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Theobromine; Xanthines; Purinones; Purines

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain shams University, Cairo, Egypt.

Study Record Dates

• First Submitted: December 18, 2025
• First Posted: January 2, 2026
• Study Start: February 1, 2023
• Primary Completion: August 31, 2023
• Study Completion: August 31, 2023
• Last Updated: January 2, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)